drugset
drugset / Trial / NCT05000346

Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms

NCT05000346 ↗

Phase 2 Terminated 21 enrolled Aquilon Pharmaceuticals S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double-blind parallel trial to assess the efficacy and safety of inhaled AQ001S in the management of acute COVID-19 symptoms compared.

Timeline

Start
2021-11-04
Primary completion
2022-12-21
Completion
2022-12-21

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of patient to recruit”

Drugs

EvaluationDrugModalityDoseRoute
Subject AQ001S Unknown 0.125 mg/ml Inhaled

Indications

COVID-19